[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,57,113,140,162,193,236,263,287,311],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100568408","phase-2-a-phase-2-study-and-open-label-extension-of-neu-411-in-companion-diagnostic-positive-participants-with-early-parkinsons-disease-100568408",false,"NCT06680830","A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)","NEULARK","Inclusion Criteria:\n\n1. Aged 40-80 years at time of screening, inclusive\n2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)\n3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx)\n4. Modified Hoehn and Yahr (mH\\&Y) of 1 to 2.5\n\nExclusion Criteria:\n\n1. Secondary or atypical parkinsonian syndromes\n2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) \\>8%\n3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)\n\nAdditional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.","ALL","40 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the \"leucine-rich repeat kinase 2\" (\"LRRK2\" for short) pathway based on their genetic profile. A DNA test will be used to identify the \"LRRK2-driven\" population with predicted elevation in the LRRK2 pathway.",[28,29,30,31,32],"Parkinson Disease","Parkinson","Idiopathic Parkinson Disease","Early Parkinson Disease (Early PD)","Parkinson Disease, Idiopathic",[34,35,36,37,38,39,15,40,41,42,43],"Early PD","Parkinsons","Parkinsons Disease","Idiopathic Parkinsons Disease","leucine-rich repeat kinase 2","PD","LRRK2","PARK8","de novo Parkinsons disease","Parkinson's disease","RECRUITING","2026-06-29",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":48},"2025-01-17",{"date":52,"type":22},"2028-06",{"name":54,"class":55},"Neuron23 Inc.","INDUSTRY",70,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":97,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","18 Years",{"count":67,"type":22},500,[69],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[72,73,74,75,76,77,78,79,80,81,82,83,29,84,85,86,87,88,89,90,91,92,93,94,95,96],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[98,99,76,77,100,36,89,101,81,95,92,102],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Diabetic Neuropathy","Neurodegeneration","2026-06-24",{"date":105,"type":48},"2026-06-26",{"date":107,"type":48},"2016-06",{"date":109,"type":22},"2028-07-31",{"name":111,"class":55},"MD Stem Cells",3,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100609628","colonic-tissue-biopsy-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-or-rem-sleep-behavior-disorder-100609628","NCT07217054","Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder","Detection of Phosphorylated Alpha-Synuclein in Colonic Tissue Biopsy During Routine Colonoscopy","Syn-G","Inclusion Criteria:\n\n1. Relatively healthy men and women ≥40-99 years of age\n2. Patients with a diagnosis of\n\n   1. Clinically confirmed PD or\n   2. Clinically confirmed RBD with no diagnosis of PD, DLB or MSA\n3. Patients must have agreed to undergo a routine colonoscopy as part of their screening or surveillance for colon cancer or for diagnostic purposes for the exclusion of other GI diseases\n\nExclusion Criteria:\n\n1. Use of anticoagulants (Plavix or aspirin alone is allowed)\n2. Under active treatment for colon cancer; 30-day post anti-cancer treatment allowed\n3. Current, ongoing gastrointestinal illness\n4. Recent intrabdominal surgery\n5. Pregnant or planning to become pregnant before the scheduled colonoscopy\n6. Significant cognitive impairment, as determined by study investigators","99 Years",{"count":123,"type":22},40,"OBSERVATIONAL","The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease and RBD?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems and RBD by loss of muscle atonia during REM sleep, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[127,29,128,28],"PARKINSON DISEASE (Disorder)","Parkinson s Disease","2026-02-09",{"date":131,"type":48},"2026-02-11",{"date":133,"type":48},"2025-11-04",{"date":135,"type":22},"2029-10",{"name":137,"class":138},"CND Life Sciences","OTHER",1,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":119,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":147,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":139},"100608676","colonoscopic-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-100608676","NCT07204652","Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis","Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders","Inclusion Criteria:\n\n* Adults 40 to 99 years of age\n* Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria\n* Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases\n\nExclusion Criteria:\n\n* Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)\n* History of colon cancer\n* Recent gastrointestinal illness or surgical procedures\n* Pregnant or planning to become pregnant before the scheduled colonoscopy\n* Significant cognitive impairment, as determined by study investigators\n* Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes",{"count":148,"type":22},20,"The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[127,29,151,28],"Parkinson's Disease and Parkinsonism",[29,153,154,155],"Parkinson's Disease","Parkinson disease","Parkinson Disease (Disorder)",{"date":131,"type":48},{"date":158,"type":48},"2025-09-03",{"date":160,"type":22},"2029-09",{"name":137,"class":138},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":17,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":139},"100623922","optimistic-and-pessimistic-dopamine-signals-in-the-human-brain-a-mapping-and-modelling-study-in-health-and-parkinsons-disease-100623922","NCT07402928","Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","OPD","PD PATIENTS:\n\nInclusion Criteria:\n\n* At least 35 years of age.\n* Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease\n* Akinetic-rigid type PD\n* Stable antiparkinsonian medicine for 4 weeks without major side effects such as dyskinesia or on-off periods.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Female participants of childbearing age must not be pregnant, and they must use contraception.\n* Breastfeeding.\n* History of other neurologic or psychiatric disease other than depression.\n* Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans.\n* Patients receiving advanced PD treatment such as duodopa pump or apomorphine pen\n* Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine).\n* Severe depression (MDI score \\> 29).\n* Refuse to be informed about new health-related findings that might appear through participation.\n\nHEALTHY CONTROLS:\n\nInclusion criteria:\n\n* At least 35 years of age.\n* Signed informed consent.\n\nExclusion criteria:\n\n* Female participants of childbearing age must not be pregnant, and they must use contraception.\n* Breastfeeding.\n* History of neurologic or psychiatric disease other than depression.\n* Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans.\n* Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine).\n* Severe depression (MDI score \\> 29).\n* Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation.",true,"35 Years",{"count":172,"type":22},140,"The goal of this observational study is to investigate whether the healthy human brain shows a diversity of optimistic and pessimistic reward signals and whether changes in this distribution in Parkinson's disease (PD) can provide mechanistic insights into the cause of symptoms.\n\nThe main hypotheses it aims to test are:\n\n1. As shown in mice, a diversity of optimistic and pessimistic dopamine reward signals exists in the human ventral tegmental area (VTA) and the ventro-rostral basal ganglia circuit.\n2. Pessimistic neurons are more severely affected by neurodegeneration in PD.\n\nResearchers will compare the diversity of optimistic and pessimistic dopamine reward signals in patients with PD and healthy participants to see if there is a skewed distribution of optimistic and pessimistic reward signals in PD. Participants will play a task probing reward- and movement related brain activity in an MRI scanner. Researchers will derive functional topographic maps of optimism\u002Fpessimism in VTA, substantia nigra pars compacta (SNc), striatum and cortical areas such as the anterior cingulate cortex (ACC).\n\nIn sub-study 1, participants will be tested on one study day where patients with PD are tested in the off-medication state (40 control participants, 40 patients with PD).\n\nIn sub-study 2, to test whether\u002Fhow dopaminergic medication affects the distribution of optimism\u002Fpessimism, participants will be tested on two study days (30 control participants, 30 patients with PD). Patients with PD are tested one day in the off-medication state, another day in the on-medication state (order counterbalanced between patients with PD). Control participants are tested on two days without medication challenge to test for test-retest effects.",[175,29,176],"Healthy","Medication Administration",[178,179,180,181,182,183,184],"dopamine","reinforcement learning","distributional reinforcement learning","reward prediction error","reward","fMRI","parkinson","2026-02-04",{"date":131,"type":48},{"date":188,"type":48},"2025-06-02",{"date":190,"type":22},"2027-06-30",{"name":192,"class":138},"Danish Research Centre for Magnetic Resonance",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":210,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":139},"100621337","comparing-biomarker-guided-dbs-programming-with-standard-clinical-monopolar-programming-100621337","NCT07369310","Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming","Randomized Trial on DBS Programming Based on Biomarkers vs. Standard Monopolar Review","Inclusion Criteria:\n\n* Age between 30 and 70 years.\n* Confirmed diagnosis of idiopathic Parkinson's disease according to the MDS diagnostic criteria (Postuma et al., 2015).\n* Indication for deep brain stimulation surgery based on CAPSIT-PD criteria.\n\nExclusion Criteria:\n\n* Presence of severe surgical complications (e.g., intracranial hemorrhage, infection).\n* Postoperative adverse events requiring electrode repositioning.\n* Any other medical or neurological condition that could interfere with safe participation in the trial.","30 Years","70 Years",{"count":148,"type":22},[69],"The goal of this clinical trial is to learn whether an objective, data-guided approach to programming deep brain stimulation (DBS) can improve motor outcomes in people with Parkinson's disease who undergo DBS surgery. The study includes adults aged 30 to 70 years with Parkinson's disease who are candidates for DBS.\n\nThe main questions it aims to answer are:\n\nDoes DBS programming based on objective markers (brain imaging and brain signals) reduce the amount of daily time patients spend in the OFF state more than conventional clinical programming?\n\nDoes this programming approach improve quality of life and motor symptoms compared with standard programming?\n\nResearchers will compare conventional DBS programming based on clinical monopolar review with DBS programming guided by electrode location on neuroimaging and beta brain signals recorded from the implanted device, to see if the objective approach leads to better motor control and less OFF time.\n\nParticipants will:\n\nUndergo DBS surgery using a clinically approved DBS system\n\nBe randomly assigned to one of two DBS programming strategies\n\nWear inertial sensors at home for several days at different time points to objectively measure motor symptoms\n\nAttend scheduled clinical visits for DBS programming and motor and non-motor assessments\n\nHave adaptive DBS activated after 3 months and continue follow-up until 6 months after programming begins",[153,29,206,207,208,209],"Parkinsons Disease (PD)","Motor Fluctuations","DBS","Deep Brain Stimulation",[153,209,211,212,213,214,215,216,217,218,219,220,221,207,222,223,224,225],"DBS Programming","Monopolar Review","Local Field Potentials","Beta Oscillations","BrainSense","Medtronic Percept","Neuroimaging-Guided Programming","Objective Programming","Adaptive Deep Brain Stimulatoin","Wearable Sensors","Inertial Sensors","OFF Time","Dyskinesia","Neuromodulation","Subthalamic Nucleus","NOT_YET_RECRUITING","2026-01-26",{"date":229,"type":48},"2026-01-27",{"date":231,"type":22},"2026-03-01",{"date":233,"type":22},"2028-09-01",{"name":235,"class":138},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":244,"targetDuration":246,"studyType":124,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":139},"100574158","transforming-parkinsons-care-with-predictive-algorithms-100574158","NCT06755645","Transforming Parkinson's Care With Predictive Algorithms","Revolutionizing Patient Care and Lifestyle Through Predictive Algorithms in Parkinson's Disease","TechHealthPD","Inclusion Criteria:\n\n* Patients with Parkinson's disease\n\nExclusion Criteria:\n\n* N\u002FA",{"count":245,"type":22},200,"1 Year","Lifestyle interventions can alleviate Parkinson's Disease (PD) symptoms and delay disease progression. The novelty of this project lies in the development of an innovative smart platform that utilizes artificial intelligence (AI) and predictive models to offer a groundbreaking solution that not only prevents disease progression but also significantly improves the well-being of patients with PD. For this, the technological smart platform will encompass 50 clinical variables, and a comprehensive range of other 50 supplementary variables, validated in a database with more than 1500 patients. The smart platform will include a user-friendly interface with different user profiles and a scalable back end with AI-based monitoring and prediction modules. This will offer primary prevention, early detection, and ongoing monitoring by specialized medical professionals at home and in hospitals.",[29],[250,251,252,253],"healthy habits","physical activity","artificial intelligence","smart platform","2025-11-27",{"date":256,"type":48},"2025-12-01",{"date":258,"type":22},"2026-09",{"date":260,"type":22},"2028-09",{"name":262,"class":138},"University Ramon Llull",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":269,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":139},"100604375","which-tools-better-predict-fall-risk-in-parkinsons-disease-a-comparative-study-of-objective-self-reported-and-functional-balance-assessment-100604375","NCT07148700","Which Tools Better Predict Fall Risk in Parkinson's Disease: A Comparative Study of Objective, Self-Reported, and Functional Balance Assessment","Inclusion Criteria:\n\n* Age between 40 and 80 years old\n* Receiving stable dopaminergic treatment\n* No other neurological disorders besides PD\n* A Standardized Mini-Mental State Examination (MMSE) score \\>24\n* Hoehn and Yahr stage between 1-3\n* Voluntarily agreed to participate in the study after receiving detailed information\n\nExclusion Criteria:\n\nPresence of visual, hearing impairments, cardiovascular or pulmonary diseases that could affect study outcomes\n\n* Having mental or physical impairments severe enough to hinder communication\n* Clinically unstable condition within the past month\n* Participation in a rehabilitation program within the last six months",{"count":123,"type":22},"Introduction: Falls are common in Parkinson's disease (PD), affecting 30-90% of patients annually, with more than half experiencing recurrent falls. Identifying balance assessment tools that are both practical and predictive of fall risk is therefore essential. This study aimed to investigate the relationship between fall frequency and three balance assessment tools: the Biodex Balance System (objective), the Falls Efficacy Scale-International (FES-I) (self-reported), and the Mini-Balance Evaluation Systems Test (Mini-BESTest) (functional).\n\nMethods: Patients with PD at Hoehn and Yahr stages 1-3 will be included in the study. Fall data will be collected using a fall diary, while objective balance will be assessed with the Biodex Balance System, functional performance will be evaluated with the Mini-BESTest, and self-reported balance confidence will be measured with the FES-I.",[127,29,128,28,272],"Parkinson Disease (PD)",[274,275,154,276,277],"Balance assessment","Functional test","Postural stability","Risk of falls","2025-08-28",{"date":280,"type":48},"2025-08-29",{"date":282,"type":48},"2025-05-01",{"date":284,"type":22},"2025-08-30",{"name":286,"class":138},"Bezmialem Vakif University",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":169,"sex":17,"minAge":294,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":139},"100461292","neuroplasticity-in-parkinsons-disease-100461292","NCT05286736","Neuroplasticity in Parkinson's Disease","Plasticity of Motor Systems in Early Stage Parkinson's Disease","Inclusion Criteria:\n\nParticipants with PD\n\n* Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria\n* Not receiving levodopa or dopamine agonist to treat PD (at baseline)\n* Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls\n* Age- (+\u002F- 3 years) and sex-matched to participants with PD\n* Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters\n\nExclusion Criteria:\n\n* Dementia diagnosis and\u002For a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent\n* History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment\n* History of bipolar disorder, post-traumatic stress disorder or major depressive disorder\n* Other significant neurological disorders that may affect participation or performance in the study\n* Implanted DBS or other neurosurgeries to treat PD\n* Pregnancy\n\nAdditional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions):\n\n* History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury\n* Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.\n* Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)\n* Pacemaker or any implanted device\n* History of surgery on blood vessels, brain, or heart\n* Unexplained, recurring headaches or concussion within the last six months\n* Severe hearing impairment","21 Years","75 Years",{"count":297,"type":22},50,"The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.",[29,28],[301],"Parkinson's","2025-08-06",{"date":304,"type":48},"2025-08-08",{"date":306,"type":48},"2021-03-01",{"date":308,"type":22},"2028-11-09",{"name":310,"class":138},"University of Minnesota",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":336,"locationsCount":139},"100570305","mediterranean-diet-effects-on-parkinsons-disease-100570305","NCT06705517","Mediterranean Diet Effects on Parkinson's Disease","Mediterranean Diet Effects on Parkinson's Disease (MED-PARK): a Randomized Controlled Trial","MED-PARK","Inclusion Criteria:\n\n1. PD diagnosis according to international guidelines;\n2. Age between 40 and 85 years;\n3. Naive to medication or with a stable dosage of anti-Parkinson's therapy for at least two weeks;\n4. Hoehn \\& Yahr stage ≤3;\n5. Normal independent feeding;\n6. Ability to complete informed consent;\n7. Willingness to maintain the usual diet in the period between T0 and T1;\n8. Willingness to maintain the usual diet if randomized to the control group in the T1-T2 period;\n9. Willingness to make changes in their diet to follow a Mediterranean diet if randomized to the intervention group in the T1-T2 period;\n10. Willingness to fill out questionnaires;\n11. Willingness to provide blood samples during the study collection periods;\n12. Willingness to provide stool samples during the study collection periods;\n13. Willingness to fast (without food or drink except water, tea or coffee) at least 12 hours before each sample collection;\n14. Willingness to discontinue taking supplements, probiotics, herbal or high- dose vitamins or minerals that could impact inflammation during the period between T0 and T1 and for the duration of the study protocol;\n15. No medical and\u002For social conditions that could interfere with participation in a six-month interventional study.\n\nExclusion Criteria:\n\n1. Atypical or secondary parkinsonism;\n2. Underweight (\\\u003C18.5);\n3. Obesity (BMI\\>30);\n4. Pregnancy or suspected pregnancy;\n5. Normal assisted nutrition;\n6. Enteral nutrition;\n7. Chronic autoimmune diseases;\n8. Chronic use of immunosuppressive drugs in the past year;\n9. Chronic use of cytotoxic cancer drugs in the past year;\n10. Major abdominal surgeries;\n11. Concurrent participation in other interventional studies;\n12. Intentional change in diet after PD diagnosis.","85 Years",{"count":321,"type":22},44,[69],"Currently, there are no disease-modifying treatments for Parkinson's disease (PD), the second most common neurodegenerative disorder worldwide, making it crucial to find interventions that can change the disease's trajectory. Epidemiological studies suggest that the Mediterranean diet (MD) is linked to improved motor and non-motor symptoms, slower disease progression, and lower mortality in PD patients. However, few interventional studies have explored this connection. This study assesses whether an MD can improve motor and non-motor symptoms in PD patients. Additionally, the study will examine the effects of the diet on a patient's quality of life, gastrointestinal symptomatology, adaptive immune system, fecal and nasal microbiome, and fecal and urinary metabolomics.\n\nThis is a randomized, controlled, non-pharmacological, single-center, masked trial with two parallel groups. It will evaluate the safety and efficacy of the MD on motor and non-motor symptoms reported by PD patients. Forty-four participants, aged 40-85, meeting the inclusion criteria will be enrolled and block-randomized into two groups: one maintaining their usual diet (control) and the other following a MD for six months (intervention).\n\nThe primary outcome is patient-reported symptoms, measured using the MDS-UPDRS I+II score.\n\nSecondary outcomes include the analysis of adaptive immune system cells, nasal and fecal microbiome composition, and inflammatory and metabolic markers. Additional assessments include disease severity (MDS-UPDRS), non-motor symptoms (Non-Motor Symptoms Scale), participant well-being (36-Item Short Form Health Survey), gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale and Patient Assessment of Constipation Quality of Life), and the intensity of dopaminergic therapy (levodopa equivalents). Evaluations will be performed at baseline and after six months.",[29,28,32,127],[326,327,29,154,328,329,330],"Diet","Mediterranean Diet","MIND diet","plant based diet","unprocessed diet","2025-07-08",{"date":333,"type":48},"2025-07-11",{"date":50,"type":48},{"date":258,"type":22},{"name":337,"class":138},"Università degli Studi dell'Insubria"]